Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

Completed · Phase 1

Conditions studied: Hepatic Insufficiency

In brief

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

Key facts

Study ID

NCT00692341

Run by

Pfizer

People needed

24

Starts

2008-05-01

Expected to finish

2008-10-01

Last updated by the study team

2012-04-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of reduced hepatic function (Child Pugh Classification A or B)
• Body Mass Index of 18-32 kg/m2

You may not qualify if…

• History of febrile illness within 5 days prior to first dose
• Any condition possibly affecting drug absorption (e.g. gastrectomy)
• Positive urine drug screen

Where it is running

• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.